@article{ff89954fd5324ebca7b7c25cbb293d6c,
title = "Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci",
abstract = "Genetic risk loci have been identified for a wide range of diseases through genome-wide association studies (GWAS), but the relevant functional mechanisms have been identified for only a small proportion of these GWAS-identified loci. By integrating results from the largest current GWAS of chronic obstructive disease (COPD) with expression quantitative trait locus (eQTL) analysis in whole blood and sputum from 121 subjects with COPD from the ECLIPSE Study, this analysis identifies loci that are simultaneously associated with COPD and the expression of nearby genes (COPD eQTLs). After integrative analysis, 19 COPD eQTLs were identified, including all four previously identified genome-wide significant loci near HHIP, FAM13A, and the 15q25 and 19q13 loci. For each COPD eQTL, fine mapping and colocalization analysis to identify causal shared eQTL and GWAS variants identified a subset of sites with moderate-to-strong evidence of harboring at least one shared variant responsible for both the eQTL and GWAS signals. Transcription factor binding site (TFBS) analysis confirms that multiple COPD eQTL lead SNPs disrupt TFBS, and enhancer enrichment analysis for loci with the strongest colocalization signals showed enrichment for blood-related cell types (CD3 and CD4+ T cells, lymphoblastoid cell lines). In summary, integrative eQTL and GWAS analysis confirms that genetic control of gene expression plays a key role in the genetic architecture of COPD and identifies specific blood-related cell types as likely participants in the functional pathway from GWAS-associated variant to disease phenotype.",
author = "Castaldi, {Peter J.} and Cho, {Michael H.} and Xiaobo Zhou and Weiliang Qiu and Michael Mcgeachie and Bartolome Celli and Per Bakke and Amund Gulsvik and Lomas, {David A.} and Crapo, {James D.} and Beaty, {Terri H.} and Stephen Rennard and Benjamin Harshfield and Christoph Lange and Dave Singh and Ruth Tal-singer and Riley, {John H.} and John Quackenbush and Raby, {Benjamin A.} and Carey, {Vincent J.} and Silverman, {Edwin K.} and Hersh, {Craig P.}",
note = "Funding Information: employees and shareholders of GlaxoSmithKline. D.S. has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CIPLA, Forest, Gen-etech, GlaxoSmithKline, Merck, Novartis, Pfizer and Takeda. Since 2011, SR reports relationships with the following companies and institutions: AARC, American Board of Internal Medicine, Able Associates, Align2 Acton, Almirall, APT, AstraZeneca, American Thoracic Society, Beilenson, Boehringer Ingelheim, Chiesi, CIPLA, Clarus Acuity, CME Incite, COPDFoundation, Cory Paeth, CSA, CSL Behring, CTS Carmel, Dailchi Sankyo, Decision Resources, Dunn Group, Easton Associates, Elevation Pharma, FirstWord, Forest, GLG Research, Gilead, Globe Life Sciences, GlaxoSmithKline, Guidepoint, Health Advance, Health-Star, HSC Medical Education, Johnson and Johnson, Leerink Swan, LEK, McKinsey, Medical Knowledge, Medimmune, Merck, Navigant, Novartis, Nycomed, Osterman, Pearl, Peer-Voice, Penn Technology, Pennside, Pfizer, Prescott, Pro Ed Communications, PriMed, Pulmatrix, Quadrant, Regeneron, Saatchi and Saatchi, Sankyo, Schering, Schlesinger Associates, Shaw Science, Strategic North, Summer Street Research, Synapse, Takeda, Telecon SC, ThinkEquity. In the past 3 years, EKS received honoraria and consulting fees from Merck and grant support and consulting fees from GlaxoSmithKline. D.A.L. is a consultant for and receives honoraria and grant support from GSK. He is the Chair of the GSK Respiratory Area Therapy Board. Funding Information: This work was supported by US National Institutes of Health (NIH) grants K08HL102265 and R01HL124233 (P.J.C.), K08HL097029 (M.H.C.), R01HL094635 (C.P.H.), R01NR013377 (C.P.H), R01 HL086601 (B.A.R.), P01HL105339 (E.K.S.), R01HL111759 (J.Q., E.K.S), R01HL089897 (J.D.C) and R01HL089856 (E.K.S). Additional support was provided by a grant from the Parker B Francis Foundation (M.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The COPDGenew project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens and Sunovion. The ECLIPSE study was supported by GlaxoSmithKline. Publisher Copyright: {\textcopyright} The Author 2014. Published by Oxford University Press. All rights reserved.",
year = "2015",
month = feb,
day = "15",
doi = "10.1093/hmg/ddu525",
language = "English (US)",
volume = "24",
pages = "1200--1210",
journal = "Human molecular genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "4",
}